Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,693 result(s) found for: placebo. Displaying page 232 of 635.
    «« First « Previous 228  229  230  231  232  233  234  235  236  Next» Last»»
    EudraCT Number: 2019-000944-82 Sponsor Protocol Number: MK-3475-966 Start Date*: 2020-03-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectabl...
    Medical condition: Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10004655 Biliary carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-005119-42 Sponsor Protocol Number: MO39193 Start Date*: 2018-01-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOC...
    Medical condition: Triple-Negative Breast Cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Completed) FI (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004946-83 Sponsor Protocol Number: BR.31 Start Date*: 2015-02-19
    Sponsor Name:Clinipace GLobal Ltd.
    Full Title: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
    Medical condition: Completely resected non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017930-35 Sponsor Protocol Number: AB06002 Start Date*: 2010-06-29
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and ...
    Medical condition: Multiple Myeloma relapsing after one previous line therapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) AT (Completed) DE (Prematurely Ended) BE (Prematurely Ended) ES (Completed) IT (Completed) GR (Completed) HU (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001976-48 Sponsor Protocol Number: IM011023 Start Date*: 2018-08-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.0 10017947 - Gastrointestinal disorders 10011398 Crohn's LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) FR (Completed) ES (Ongoing) PL (Completed) DE (Completed) DK (Prematurely Ended) PT (Completed) NL (Completed) BE (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001272-37 Sponsor Protocol Number: 0173 Start Date*: 2019-01-10
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderate...
    Medical condition: Moderately-to-Severely Active Crohn’s Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PT (Completed) ES (Prematurely Ended) HU (Prematurely Ended) BG (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Ongoing) GR (Completed) HR (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004616-12 Sponsor Protocol Number: CCDZ173X2203 Start Date*: 2016-05-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome
    Medical condition: Primary Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024179-18 Sponsor Protocol Number: A0221094 Start Date*: 2011-05-31
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DE (Completed) CZ (Completed) FI (Completed) GR (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003626-24 Sponsor Protocol Number: MK-3102-011 Start Date*: 2013-01-25
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) NL (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004084-39 Sponsor Protocol Number: 1002-048 Start Date*: 2017-04-19
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patie...
    Medical condition: This study is to assess the efficacy of bempedoic acid 180 mg/day versus placebo in decreasing low-density lipoprotein cholesterol (LDL-C) when added to ezetimibe therapy in patients with high LDL-...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    19.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003154-40 Sponsor Protocol Number: MK-4305-061 Start Date*: 2017-01-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer’s Disease
    Medical condition: Insomnia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10022437 Insomnia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021003-24 Sponsor Protocol Number: 20100754 Start Date*: 2011-07-28
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dys...
    Medical condition: Acute heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) GB (Completed) LT (Completed) FI (Prematurely Ended) SK (Completed) CZ (Completed) HU (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-006474-28 Sponsor Protocol Number: NBI-56418-0703 Start Date*: 2008-05-14
    Sponsor Name:Neurocrine Biosciences, INC
    Full Title: A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects with Endometriosis
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014778 Endometriosis LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004161-68 Sponsor Protocol Number: AG013-ODOM-201 Start Date*: 2018-10-31
    Sponsor Name:Oragenics, Inc.
    Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance...
    Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004532-30 Sponsor Protocol Number: MRZ60201_3091_1 Start Date*: 2014-12-09
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of...
    Medical condition: Chronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10039424 Salivary hypersecretion PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002118-40 Sponsor Protocol Number: PPL07 Start Date*: 2018-02-23
    Sponsor Name:Dilafor AB
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of continuous infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 hours...
    Medical condition: Primary Slow Progress of Labor including prolonged latent phase and Primary Labor Arrest
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004868 10023539 Labor abnormal LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002772-14 Sponsor Protocol Number: COX189A2367 Start Date*: 2005-11-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 13-week, multicenter, randomized, double-blind, doubledummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecox...
    Medical condition: Primary osteoarthritis of the hip
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018999-25 Sponsor Protocol Number: PGL09-026 Start Date*: 2010-07-13
    Sponsor Name:PregLem S.A.
    Full Title: Estudio multicéntrico de fase III para investigar la eficacia y la seguridad del tratamiento abierto de 3 meses con PGL4001, seguido de un periodo aleatorizado, doble ciego y controlado con placebo...
    Medical condition: Los miomas uterinos son tumores benignos, monoclonales y sensibles a las hormonas, del músculo liso del útero. Son los miomas que aparecen con más frecuencia en el aparato reproductor femenino en l...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) PL (Completed) AT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001969-17 Sponsor Protocol Number: VML 251-3MRM02 Start Date*: 2005-01-10
    Sponsor Name:Vernalis Development Limited
    Full Title: A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-r...
    Medical condition: Menstrually-Related Migraine (MRM)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003655-36 Sponsor Protocol Number: CQVA149A2204 Start Date*: 2008-02-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 228  229  230  231  232  233  234  235  236  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 13:20:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA